WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004031222) DNA VACCINE ENCODING AT LEAST TWO NONSTRUCTURAL EARLY PROTEINS OF PAPILLOMAVIRUS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/031222    International Application No.:    PCT/EP2003/011158
Publication Date: 15.04.2004 International Filing Date: 01.10.2003
Chapter 2 Demand Filed:    08.04.2004    
IPC:
A61K 39/00 (2006.01), C07K 14/025 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB) (For All Designated States Except US).
GOUGH, Gerald, Wayne [GB/GB]; (GB) (For US Only).
ROBERTS, Christopher, Michael [GB/GB]; (GB) (For US Only)
Inventors: GOUGH, Gerald, Wayne; (GB).
ROBERTS, Christopher, Michael; (GB)
Agent: DALTON, Marcus, J., W.; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB)
Priority Data:
0222953.2 03.10.2002 GB
Title (EN) DNA VACCINE ENCODING AT LEAST TWO NONSTRUCTURAL EARLY PROTEINS OF PAPILLOMAVIRUS
(FR) VACCIN
Abstract: front page image
(EN)The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections. In particular the invention relates to nucleic acid molecules encoding E1 and/or E2 and vectors suitable for DNA vaccine delivery, and pharmaceutical compositions containing them. Methods for manufacturing said molecules, vectors and composition are also contemplated.
(FR)La présente invention concerne des techniques et des compositions qui conviennent pour le traitement et la prévention des infections par le papillomavirus humain. Cette invention concerne, en particulier, des molécules d'acides nucléiques codantes pour E1 et/ou E2 et des vecteurs adaptés pour l'apport de vaccin à ADN et, des compositions pharmaceutiques contenant ces molécules. Cette invention concerne aussi des techniques de fabrication de ces molécules, de ces vecteurs et de cette composition.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)